IS8351A - Lyfjaafurðir sem fela í sér bisfosfónöt - Google Patents
Lyfjaafurðir sem fela í sér bisfosfónötInfo
- Publication number
- IS8351A IS8351A IS8351A IS8351A IS8351A IS 8351 A IS8351 A IS 8351A IS 8351 A IS8351 A IS 8351A IS 8351 A IS8351 A IS 8351A IS 8351 A IS8351 A IS 8351A
- Authority
- IS
- Iceland
- Prior art keywords
- products containing
- pharmaceutical products
- containing bisphosphonates
- bisphosphonates
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50440203P | 2003-09-18 | 2003-09-18 | |
PCT/EP2004/010470 WO2005025551A2 (en) | 2003-09-18 | 2004-09-17 | Pharmaceutical products comprising bisphosphonates |
Publications (1)
Publication Number | Publication Date |
---|---|
IS8351A true IS8351A (is) | 2006-03-13 |
Family
ID=34312464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8351A IS8351A (is) | 2003-09-18 | 2006-03-13 | Lyfjaafurðir sem fela í sér bisfosfónöt |
Country Status (23)
Country | Link |
---|---|
US (1) | US7932241B2 (is) |
EP (1) | EP1663314A2 (is) |
JP (1) | JP4802096B2 (is) |
KR (1) | KR101015718B1 (is) |
CN (1) | CN1852739A (is) |
AR (1) | AR045670A1 (is) |
AU (1) | AU2004271731B2 (is) |
BR (1) | BRPI0414562A (is) |
CA (1) | CA2536206C (is) |
CO (1) | CO5680461A2 (is) |
EC (1) | ECSP066419A (is) |
IL (1) | IL173766A (is) |
IS (1) | IS8351A (is) |
MA (1) | MA28078A1 (is) |
MY (1) | MY141763A (is) |
NO (1) | NO20061682L (is) |
NZ (1) | NZ545343A (is) |
PE (1) | PE20050468A1 (is) |
RU (1) | RU2358739C2 (is) |
TN (1) | TNSN06084A1 (is) |
TW (1) | TWI345977B (is) |
WO (1) | WO2005025551A2 (is) |
ZA (1) | ZA200601209B (is) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119230A1 (en) * | 2003-09-18 | 2005-06-02 | Alexandra Glausch | Pharmaceutical products comprising bisphosphonated |
MY141763A (en) | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
EP2114368A1 (en) * | 2006-11-17 | 2009-11-11 | Besins Healthcare | Pharmaceutical compositions comprising a bisphosphonate compound |
EP1923049A1 (en) * | 2006-11-17 | 2008-05-21 | Besins Healthcare | Pharmaceutical compositions comprising a bisphosphonate compound |
SI3345607T1 (sl) * | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
JP5607408B2 (ja) * | 2009-04-03 | 2014-10-15 | 帝人ファーマ株式会社 | アレンドロン酸含有注射剤 |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
ES2650665T3 (es) | 2009-07-31 | 2018-01-19 | Grünenthal GmbH | Método de cristalización y biodisponibilidad |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
EP2363111A1 (en) | 2010-03-01 | 2011-09-07 | Combino Pharm, S.L. | Stable pharmaceutical composition comprising bisphosphonate |
WO2011132826A1 (en) * | 2010-04-19 | 2011-10-27 | Snu R&Db Foundation | Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases |
WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
EP2712611A1 (en) | 2012-09-27 | 2014-04-02 | B. Braun Melsungen AG | Stabilized aqueous compositions of neuromuscular blocking agents |
RU2506085C1 (ru) * | 2013-01-30 | 2014-02-10 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Тетраэтил-2-(2,2,6,6-тетраметилпиперидин-4-иламино)-этилен-1,1-бисфосфонат, обладающий противоопухолевой активностью |
CN104721132B (zh) * | 2013-12-21 | 2018-05-18 | 石药集团恩必普药业有限公司 | 一种唑来膦酸注射液及其制备方法 |
US10098813B2 (en) * | 2014-09-03 | 2018-10-16 | Sun Pharmaceutical Industries Limited | Perfusion dosage form |
GB201505347D0 (en) * | 2015-03-27 | 2015-05-13 | Salupont Consulting Ltd | Sterilisation of s-nitrosothiols |
CN108261393B (zh) * | 2015-09-27 | 2020-10-27 | 山东则正医药技术有限公司 | 一种含有唑来膦酸的注射用药物组合物 |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
WO2019067145A1 (en) * | 2017-08-28 | 2019-04-04 | Asdera Llc | USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION |
CA3076821A1 (en) * | 2017-09-28 | 2019-04-04 | Asdera Llc | Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation |
CN110161168B (zh) * | 2018-02-12 | 2022-12-20 | 四川科伦药物研究院有限公司 | 唑来膦酸及其杂质的高效液相色谱检测方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0275821B1 (de) * | 1986-11-21 | 1992-02-26 | Ciba-Geigy Ag | Neue substituierte Alkandiphosphonsäuren |
JP3672342B2 (ja) * | 1994-09-26 | 2005-07-20 | アステラス製薬株式会社 | ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル |
GB0012209D0 (en) * | 2000-05-19 | 2000-07-12 | Novartis Ag | Organic compounds |
WO2002022136A1 (en) | 2000-09-18 | 2002-03-21 | F H Faulding & Co Limited | Diphosphonate solutions |
CZ20032951A3 (cs) | 2001-05-02 | 2004-02-18 | Sicor Inc. | Injikovatelný pamidronate disodium |
CA2372450A1 (en) | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
MY141763A (en) | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
-
2004
- 2004-09-15 MY MYPI20043727A patent/MY141763A/en unknown
- 2004-09-16 AR ARP040103333A patent/AR045670A1/es unknown
- 2004-09-16 PE PE2004000900A patent/PE20050468A1/es not_active Application Discontinuation
- 2004-09-17 BR BRPI0414562-3A patent/BRPI0414562A/pt not_active Application Discontinuation
- 2004-09-17 NZ NZ545343A patent/NZ545343A/en not_active IP Right Cessation
- 2004-09-17 AU AU2004271731A patent/AU2004271731B2/en not_active Ceased
- 2004-09-17 TW TW093128260A patent/TWI345977B/zh not_active IP Right Cessation
- 2004-09-17 RU RU2006112596/15A patent/RU2358739C2/ru not_active IP Right Cessation
- 2004-09-17 KR KR1020067005455A patent/KR101015718B1/ko not_active IP Right Cessation
- 2004-09-17 EP EP04765362A patent/EP1663314A2/en not_active Ceased
- 2004-09-17 US US10/570,339 patent/US7932241B2/en not_active Expired - Fee Related
- 2004-09-17 CN CNA2004800269883A patent/CN1852739A/zh active Pending
- 2004-09-17 CA CA2536206A patent/CA2536206C/en not_active Expired - Fee Related
- 2004-09-17 JP JP2006526598A patent/JP4802096B2/ja not_active Expired - Lifetime
- 2004-09-17 WO PCT/EP2004/010470 patent/WO2005025551A2/en active Application Filing
-
2006
- 2006-02-10 ZA ZA200601209A patent/ZA200601209B/en unknown
- 2006-02-16 IL IL173766A patent/IL173766A/en not_active IP Right Cessation
- 2006-03-13 IS IS8351A patent/IS8351A/is unknown
- 2006-03-13 EC EC2006006419A patent/ECSP066419A/es unknown
- 2006-03-17 TN TNP2006000084A patent/TNSN06084A1/en unknown
- 2006-03-21 CO CO06027690A patent/CO5680461A2/es unknown
- 2006-03-27 MA MA28895A patent/MA28078A1/fr unknown
- 2006-04-12 NO NO20061682A patent/NO20061682L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL173766A (en) | 2012-10-31 |
CA2536206A1 (en) | 2005-03-24 |
TWI345977B (en) | 2011-08-01 |
KR101015718B1 (ko) | 2011-02-22 |
TNSN06084A1 (en) | 2007-10-03 |
US7932241B2 (en) | 2011-04-26 |
JP2007505861A (ja) | 2007-03-15 |
NO20061682L (no) | 2006-06-14 |
MA28078A1 (fr) | 2006-08-01 |
AU2004271731A1 (en) | 2005-03-24 |
AU2004271731B2 (en) | 2008-07-24 |
PE20050468A1 (es) | 2005-10-03 |
CA2536206C (en) | 2010-08-24 |
MY141763A (en) | 2010-06-30 |
CN1852739A (zh) | 2006-10-25 |
AR045670A1 (es) | 2005-11-02 |
RU2358739C2 (ru) | 2009-06-20 |
TW200522969A (en) | 2005-07-16 |
RU2006112596A (ru) | 2007-11-10 |
US20070015736A1 (en) | 2007-01-18 |
WO2005025551A2 (en) | 2005-03-24 |
IL173766A0 (en) | 2006-07-05 |
ZA200601209B (en) | 2007-04-25 |
CO5680461A2 (es) | 2006-09-29 |
BRPI0414562A (pt) | 2006-11-07 |
JP4802096B2 (ja) | 2011-10-26 |
KR20060087568A (ko) | 2006-08-02 |
ECSP066419A (es) | 2006-09-18 |
NZ545343A (en) | 2010-08-27 |
WO2005025551A3 (en) | 2006-01-12 |
EP1663314A2 (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS8351A (is) | Lyfjaafurðir sem fela í sér bisfosfónöt | |
EG27104A (en) | Pharmaceutical compounds | |
GB0315657D0 (en) | Pharmaceutical compounds | |
IS8460A (is) | Lyfjafræðileg samsetning sem inniheldur kvetíapín | |
IS2946B (is) | Lyfjablanda sem felur í sér andrógen | |
GB0327723D0 (en) | Pharmaceutical compositions | |
GB0218625D0 (en) | Pharmaceutical compounds | |
ZA200605080B (en) | Pharmaceutical compositions | |
GB0308511D0 (en) | Pharmaceutical compounds | |
GB0300531D0 (en) | Pharmaceutical compositions | |
HK1084670A1 (en) | Pharmaceutical compositions comprising cabbinochreme type compounds | |
GB0215775D0 (en) | Pharmaceutical compounds | |
EP1648411A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
IS7458A (is) | Stöðug lyfjablanda sem inniheldur þátt VIII | |
AU307054S (en) | Pharmaceutical packaging | |
GB0316206D0 (en) | Pharmaceutical formulation | |
GB0317315D0 (en) | Pharmaceutical compounds | |
GB0313766D0 (en) | Pharmaceutical compounds | |
GB0301736D0 (en) | Pharmaceutical compounds | |
NO20034952D0 (no) | Farmasöytiske forbindelser | |
GB0305579D0 (en) | Pharmaceutical compositions | |
ZA200509741B (en) | Pharmaceutical composition comprising cyclic smatostin analogues | |
GB0328040D0 (en) | Pharmaceutical uses of bisphosphonates | |
GB0329617D0 (en) | Pharmaceutical compounds | |
GB0310361D0 (en) | Pharmaceutical compound |